[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370305-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370305-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","from-silent-partners-to-potential-therapeutic-targets-macrophages-in-colorectal-cancer","From silent partners to potential therapeutic targets - macrophages in colorectal cancer","","Colorectal cancer grows and persists within a complex tumor microenvironment where tumor-associated macrophages (TAMs) act in a double-edged manner. TAMs can support tumor progression by promoting angiogenesis, while also contributing anti-cancer effects such as direct killing, antigen presentation, and enhancement of T cell responses. Regulatory crosstalk between immune system and tumors involves hypoxia, metabolic reprogramming, cytokine/chemokine signaling, and cell interactions. Targeted strategies for TAMs include disrupting chemokine or adhesion pathways, inducing anti-tumor reprogramming via TLR or CD40 agonists, and selectively removing pro-tumor TAM subsets, while addressing drug resistance and biomarker limitations through combined macrophage-targeted regimens and multi-omics approaches.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/from-silent-partners-to-potential-therapeutic-targets-macrophages-in-colorectal-cancer/370305/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/from-silent-partners-to-potential-therapeutic-targets-macrophages-in-colorectal-cancer/370305.png","ImageObject",300,407,{"name":42,"@type":43},"Ezra","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What dual roles do tumor-associated macrophages (TAMs) play in colorectal cancer?","Question",{"text":63,"@type":64},"TAMs can promote colorectal cancer growth through angiogenesis, but they can also exert anti-cancer functions such as direct killing, antigen presentation, and supporting T cell-mediated responses.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which mechanisms shape the tumor microenvironment and TAM regulation in CRC?",{"text":68,"@type":64},"Regulation involves a network influenced by hypoxia, metabolic reprogramming, cytokine/chemokine signaling, and interactions among immune and stromal cells.",{"name":70,"@type":61,"acceptedAnswer":71},"How can TAMs be targeted for therapy in colorectal cancer?",{"text":72,"@type":64},"Therapeutic approaches include disrupting chemokine signaling or adhesion molecules, reprogramming TAMs toward an anti-tumor phenotype using TLR or CD40 agonists or metabolic modulation, and selectively removing TAM subsets that drive tumor growth.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370305,1790415810,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Cancer Immunology, Immunotherapy (2025) 74:121 [https://doi.org/10.1007/s00262-025-03965-w](https://doi.org/10.1007/s00262-025-03965-w)  \nFrom silent partners to potential therapeutic targets: macrophages in colorectal cancer  \nHayat Khizar1 · Kamran Ali1 · Jianwei Wang1,2  \nReceived: 15 November 2024 / Accepted: 30 January 2025 / Published online: 25 February 2025 © The Author(s) 2025  \nAbstract  \nCancer cells grow and survive in the tumor microenvironment, which is a complicated process. As a key part of how colorectal cancer (CRC) progresses, tumor-associated macrophages (TAMs) exhibit a double role. Through angiogenesis, this TAM can promote the growth of cancers. Although being able to modify and adjust immune cells is a great advantage, these cells can also exhibit anti-cancer properties including direct killing of cancer cells, presenting antigens, and aiding T cell-mediated responses. The delicate regulatory mechanisms between the immune system and tumors are composed of a complex network of pathways regulated by several factors including hypoxia, metabolic reprogramming, cytokine/chemokine signaling, and cell interactions. Decoding and figuring out these complex systems become significant in building targeted treatment programs. Targeting TAMs in CRC involves disrupting chemokine signaling or adhesion molecules, reprogramming them to an anti-tumor phenotype using TLR agonists, CD40 agonists, or metabolic modulation, and selectively removing TAM subsets that promote tumor growth. Multi-drug resistance, the absence of an accurate biomarker, and drug non-specificity are also major problems. Combining macrophage-targeted therapies with chemotherapy and immunotherapy may revolutionize treatment. Macrophage studies will advance with new technology and multi-omics methodologies to help us understand CRC and build specific and efficient treatments.  \nKeywords Tumor microenvironment · Tumor-associated macrophages · Colorectal cancer · Therapy  \nIntroduction  \nColorectal cancer (CRC) is a type of cancer that begins in the colon or rectum and often starts from benign growths called polyps on the inner surface of the large intestine. Over the time, some of these polyps can go through neoplastic transformation and develop into cancer. CRC accounts for 10% of mortality worldwide which makes it the third most spread cause of death [1–3] . Researchers have identified four distinct molecular subtypes of CRC  \n* Jianwei Wang [sypzju@zju.edu.cn](sypzju@zju.edu.cn)  \n1 Department of Surgery, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu 322000, China  \n2 Department of Colorectal Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, 2nd Affiliated Hospital, Zhejiang University School of Medicine, Jiefang Road 88th, Hangzhou 310009, China  \nby examining gene expression patterns. These subtypes are referred to as consensus molecular subtypes (CMS 1–4) . Different subtypes are associated with specific genes and biological pathways. These include the MSI immune subtype (CMS1), canonical subtype (CMS2), metabolic subtype (CMS3), and mesenchymal subtype (CMS4) [4] . Note that the MSI immune and metabolic groups typically relate to CRC on the right side of the colon. While conducting treatment, it is important to consider factors like the tumor’s location (whether it’s on the right or left side) and genetic changes (like mutations in RAS or RAF genes), among other factors [5 , 6] . Treatment for CRC varies based on the stage of the disease and the unique characteristics of each patient. There are various treatment options available, such as surgery, chemotherapy, radiation therapy, or precision drugs [7, 8]. The European Screening Guidelines Working Group and European Council suggest establishing screening programs for early detection of CRC and surgical intervention to improve the survival ra","cbCaiiI0gpiwliXL","https://ap.wps.com/l/cbCaiiI0gpiwliXL","pdf",2969009,14,"English","# Abstract\n# Introduction","[{\"question\":\"What dual roles do tumor-associated macrophages (TAMs) play in colorectal cancer?\",\"answer\":\"TAMs can promote colorectal cancer growth through angiogenesis, but they can also exert anti-cancer functions such as direct killing, antigen presentation, and supporting T cell-mediated responses.\"},{\"question\":\"Which mechanisms shape the tumor microenvironment and TAM regulation in CRC?\",\"answer\":\"Regulation involves a network influenced by hypoxia, metabolic reprogramming, cytokine/chemokine signaling, and interactions among immune and stromal cells.\"},{\"question\":\"How can TAMs be targeted for therapy in colorectal cancer?\",\"answer\":\"Therapeutic approaches include disrupting chemokine signaling or adhesion molecules, reprogramming TAMs toward an anti-tumor phenotype using TLR or CD40 agonists or metabolic modulation, and selectively removing TAM subsets that drive tumor growth.\"}]","From silent partners to potential therapeutic targets - macrophages in colorectal cancer | PDF",1790187889,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e6662649dc95350fcfb56f5cbb9fb9cc.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7890201065051eb2c922b8e723d0687f.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/011db7dc9f68bbdc1355b5fa3da2d6ec.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f5b919d262cc64f52396322e6af484b5.webp",980,1301]